Ladies and gentlemen, thank you for standing by. Welcome to the Genomma Lab's Q4 2021 results conference call. At this time, all participants are in listen-only mode. Following today's discussion, we will conduct a question and answer session. Instructions will be provided at that time for you to queue up for questions. If anyone should require operator assistance, please press star zero on your telephone keypad. A replay will also be available shortly after the conclusion of the call. I'll now turn the call over to Barbara Cano with the InspIR Group. Please go ahead, Barbara. Thank you and good morning. We'll begin today's discussion with remarks from Jorge Brake, Genomma Lab's Chief Executive Officer, followed by Antonio Zamora, Chief Financial Officer, and we'll close with the question-and-answer session. Our call will include projections and other forward-looking statements, and it's important to note that actual results could differ materially from those projected. Genomma undertakes no obligation to update or to revise publicly any forward-looking statements, whether because of new information, future events or other factors. Investors are urged to carefully review various disclosures made by the company, including the risk and other information disclosed within the company's filing with the Mexican Stock Exchange. With that, I'll now turn the call over to Mr. Jorge Brake. Jorge? Thanks, Barbara, and thank you to everyone joining today. I am pleased with our Q4 performance and our results for the year. As you read in yesterday's press release, Genomma Lab achieved historic levels of both growth and profitability in 2021. We also continued to prepare and adapt to the changing needs of our customers and at the same time focus on delivering a strong return for our shareholders. We ended the year announcing a new strategic pillar as we are unleashing the next evolution of our strategy with an evolved view of health and wellbeing for the future by leveraging partnerships with leading global companies to enter new categories while we take our partners' brands to the next level in our regions. Genomma is a health and wellbeing company that is leveraging our true understanding manufacturing, marketing and commercialization capabilities to expand our positioning beyond the traditional personal care and OTC company. As our results for the year and for the final quarter demonstrated, we will continue to leverage Genomma's innovation strengths with line extensions and new product launches through our reinforced supply chain, the strong network economics and robust product offerings. However, new alliances such as Genomma's recently announced partnership with Oramed, subsidiary of Oramed, enable us to expand beyond our traditional scope. This new inorganic component to our growth strategy therefore takes further advantage of our strength in building and distributing brands within the market we know well and partnering with global companies that have outstanding products to grow beyond what's possible through organic growth alone. Needless to say, the opportunities are exciting and we look forward to making further related announcement in the near future. Let me now discuss our very solid results for 2021. Genomma's third consecutive year of double-digit growth and profits, which are growing faster than sales in absolute terms. Full year 2021 net sales reached more than MXN 15 billion, a more than 11% year-on-year increase. EBITDA for the full year increased by more than 10% with a 21% margin driven by consistent execution of our strategy with benefit of the many interventions we made throughout our organization. We continue to see performance of innovation initiatives, particularly line extensions and a strong new category performance supported by aggressive external media campaigns and in-store marketing. To comment on just a few examples, our Cicatricure Natura shampoo with new environmentally sustainable recycled and recyclable packaging, which we unveiled last quarter, saw a double-digit increase in sales during the Q4 of 2021 as a result of this initiative. The new Carbon by Groomen launched in the Q3 is also growing share in Mexico, boosted by a grooming testimonial advertising campaign which increased second half 2021 sales by more than 50% year-on-year. We have since also launched Carbon Groomen in Chile with a favorable initial response. These are only a few examples of the power of Genomma's brand value coupled with outstanding advertising and consumer messaging launched through Genomma's multifaceted media produced in-house. 2021 sales growth, while tempered by the well-known headwinds of higher inflation, exchange rates and broad-based global supply chain challenges, was strong in most of our markets. We have also been successfully managing inflation pressures with disciplined pass through of cost increases. Antonio will discuss this in detail shortly, but I'm very proud of how our teams manage costs related to this volatility. Their strong execution combined with effective pricing actions across both segments mitigated effects to a large degree. Further, Genomma's supply chain was meaningfully bolstered by prior interventions, with a new team in place for the last year and a half and a fully redesigned supply chain model. Our enhanced demand forecasting procurement and resulting improved fill rates and service levels are supported by our new sales and operations model tool. Both the processes and related cost reductions have improved, resulting in a lower cost and higher quality finished product, particularly compared to Genomma third-party suppliers. Genomma Latin American operation ended the year maintaining prior quarter momentum, with net sales again reaching almost MXN 2 billion, a 12% year-on-year increase versus only the 2020 results, supported by double-digit growth in the whole South America. Innovation and expansion strategies, as well as increased points of sale, supported these results, which were partially offset by a negative exchange rate impact in some countries where Genomma operates. In Mexico, Q4 2021 net sales increased by 26% year-on-year, with initiatives which drove increased market share within key categories, as well as new core brand line extensions, including the examples I have already noted. This was supported by a slight recovery of cough and cold product demand in December, as Omicron symptoms were similar to a common cold for many. During the quarter, we made solid progress on our Mexico industrial cluster. Our personal care and beverage manufacturing plant is up and running. The SueroX shampoo and ointment lines have completed the initial production phase, reaching roughly 6.5 million bottles of SueroX, 470,000 bottles of shampoo, and 22,000 bottles of ointments produced per month. OTC will begin shortly, and we continue making progress on expanding with an eye towards exports and diversifying product formats, which improved overall profitability for our personal care business. Turning to our U.S. operations, Q4 2021 net sales increased by just under 2%. While we further advanced the U.S. market business model restructuring process that we began in 2020, also with a new team in place, we continue to face Omicron headwinds, delaying our full implementation. However, we believe we've reached an inflection point with increased consumption expected for the spring and better sell-out and selling optimization. SueroX at this point is performing extremely well in the U.S., expanding within points of sale in Puerto Rico, among other markets, including California, as reflected in record Q4 2021 SueroX sales. SueroX can be found in major retailers in these states, where we are a leading brand compared to competitors like Powerade and Pedialyte. Genomma's e-commerce presence increased during 2021, approaching 6% of total Q4 2021 sales. You will recall we targeted between 10% and 15% of the personal care sales for 2022, noting the general limitations that OTC product sales have through e-commerce. Finally, ESG is an important and long-standing pillar of Genomma's growth strategy. Genomma was one of the 10 Mexican companies recognized for environmental, social, and governance practices through our inclusion within the 2022 S&P Global Sustainability Yearbook for the first time. The 2022 edition assessed more than 7,500 companies across 61 industries globally and showcases the best performing companies among industry peers and in terms of financially material ESG metrics. We were also included within the Dow Jones Sustainability MILA Pacific Alliance Index for the second consecutive year. Genomma Lab's MSCI ESG rating was also upgraded to BB from B in 2021. In closing, while the environment in 2021 remained challenging, it also proved to be transformative for Genomma. We are advancing our strategic plan while adapting to a changing environment to capture exciting opportunities. Before I turn our call to Antonio for a discussion of our financial results, I would like to recognize the incredible and tireless work of all our associates and teams through continued volatility in 2021. This was indeed Genomma Lab's year of our people. With that, I will turn you over to Antonio, our CFO. Antonio? Thank you, Jorge, and good morning, everyone. 2021 was an important year for Genomma. We exceeded our financial goals, we advanced our strategy, and we brought greater value to our customers. Genomma ended a strong 2021 with another strong quarter, entering 2022 with favorable momentum. As Jorge noted, Genomma's successful growth strategy implementation throughout the regions where we operate drove an 11.5% year-on-year increase in consolidated net sales to reach MXN 15.5 billion for the full year 2021. Q4 net sales increased by 17% year-on-year to reach MXN 4.1 billion due to successful innovation initiatives such as line extensions, strong new category performance, as well as aggressive external media campaigns with solid in-store marketing for Mexico and Latin American operations. To a lesser extent, increased sales were driven by a slight recovery of the cough and cold category beginning in late December. Full year EBITDA reached MXN 3.2 billion with a 20.8% margin, a 30 basis points year-on-year decrease, primarily due to FX headwinds, raw materials and commodity inflation, and non-recurring expenses related to new product launches and e-commerce platform investments. To a lesser extent, margins decreased due to a negative product mix effect with increased sales of lower margin products, as well as investments made to begin Genomma's industrial cluster operations in Mexico. Q4 2021 EBITDA increased MXN 170 million as compared with the same audited period of 2020 to MXN 890 million due to operational leverages resulting from increased sales, a favorable product mix effect, as well as operating efficiencies. Additionally, EBITDA margin improvement was driven by price increases implemented during the Q4 2021. Along these lines, we have been managing inflationary pressures in all countries where we're present through discipline and also strategic pass-through of cost increases, notably delivering on our aim of passing through inflation to the end consumer. An example of this is Argentina, where we're seeing roughly 50% inflation a year, yet Genomma has been able to raise prices in line or even above inflation where possible with double-digit unit volume growth as well, expanding market share and profits above company averages. Turning to Mexico, we closed 2021 with Q4 net sales of MXN 1.9 billion, just short of 26%, and let me repeat that, 26% year-on-year increase. It's a very important number. This MXN 376 million increase was due to initiatives which drove increased market share within key categories, as well as new core brand line extensions, as well as slight cough and cold product demand recovery during December due to the Omicron variant common flu symptoms. Mexico EBITDA for the Q4 2021 reached MXN 423 million with a 22.6% margin, reflecting a 110 basis point year-on-year improvement, benefiting from higher operating leverage, successful cost and expense controls, price increase strategies to recover macroeconomic headwinds, and to a slight decrease in non-recurring expenses associated with Genomma's new industrial cluster. As Jorge mentioned, Q4 U.S. net sales increased by just under 2% to MXN 327 million. This was supported by an increased e-commerce presence, strong SueroX performance in Puerto Rico, as well as new product launches both in Puerto Rico and California. Our U.S. performance was adversely impacted by Q4 innovation strategies being delayed due to continued COVID-related pressures. Latin America net sales for the quarter grew by 12.5% year-on-year to MXN 1.9 billion. Strong performance was partially offset by a negative Forex impact in some countries where Genomma operates, notably Argentina, Chile, Colombia, Brazil, and Uruguay. Q4 2021 EBITDA reached MXN 452 million, with an EBITDA margin just below 24%, a 90 basis points year-on-year increase with benefit of cost and expense control and price increases to mitigate macroeconomic headwinds. Regarding our profitability, Q4 2021 gross profit increased by almost 19% to MXN 2.6 billion. The 90 basis points year-on-year gross margin increase for the Q4 was due to favorable sales mix with a slight cough and cold category recovery that I mentioned before, offset by Forex-related increases on certain input costs as well. Working capital was adjusted during the Q4 2021, and the cash conversion cycle improved by 4 days since the end of September 2021 to reach 109 days. Strengthened collections and other successful initiatives during the quarter decreased our days of consolidated accounts receivables by six days to 100. As Jorge mentioned, Genomma's improved S&OP system benefits in controls and operations strengthen our supply chain, which reflected a 24-day decrease in days of inventories that reached 130 days as of December 31st, closing at MXN 2.1 billion at year's end. Genomma closed the Q4 2021 with a leverage ratio a little bit less than 1.5 times net debt to EBITDA and MXN 1.3 billion in cash and equivalents at the quarter's end. A 40% year-on-year decrease due to debt repayment throughout the year. During the quarter, we repurchased a little bit over 2.8 million shares during the three months ended December 31st, 2021, which represents an investment of approximately MXN 53 million. Finally, Genomma paid a cash dividend for the first time in the company's history. This decision signaled the conclusion of Genomma's manufacturing plant investment phase, coupled with strong cash flow generation and no significant near-term cash investments expected. As Jorge mentioned, 2021 represented the company's third consecutive year of sustained growth since implementing Genomma's new strategy back in January 2019. In closing, our 2021 operating performance underscored the strength of our business model, the value of our products and capabilities, and the resilience of our employees. We have demonstrated that we have been able to successfully manage through pressures and did so again in the Q4 as we did in 2020 and all of 2021. We expect to do the same in the future and coping with inflationary environments using our pricing strategies and other levers that we have to fully offset cost pressures over time. With that, let me turn the call over to your questions. Operator? Our first question today is coming from Rodrigo Alcántara from UBS. Your line is now live. Hi. Good afternoon, good morning, Jorge, Antonio. Congratulations on the quarter. I have two questions here. The first one, it caught my attention on the reported growth that you mentioned in the press release on your shampoo category of Tío Nacho in Mexico, of double digits, you know, which may suggest some market share gains here. My question here is, you know, to what extent the production of the plant is responsible, and to what extent is the addition of point of sale or innovation responsible of this result. That would be my question regarding the growth you reported on conditioner category in Mexico. The second one, I just needed to ask here about the U.S., you know, if you can comment a bit about, you know, what is missing there? I mean, you mentioned about this initiative being delayed due to COVID, but if you can comment a bit more on what is left to be done or what should we expect as investors, you know, about the U.S. for 2022? Could it be a year where we see more stability there in those operations? Or any directional comment you can give about the U.S. would be really helpful. Thank you very much. Thank you. Thank you, Rodrigo. I will make a couple of comments, and then Antonio will complement as usual. On the shampoo business in Mexico, as you mentioned, we had a very good, strong quarter. I would say it's behind two or three very important things. One is the market. We are impacting the market via innovation. That is a very good example in the case of shampoos because Tío Nacho is part of that. As you know, we didn't go through this initiative with a lot of detail in the last call, but now the new Tío Nacho 100% recyclable and recycled is our first 100% sustainable brand. That is also behind our 2025 commitment in terms of sustainability. It's out there. It started shipments in Mexico exactly starting the last quarter of the year. And now it's being rolled out in other countries too as we continue expanding manufacturing production capacity for the new version. That also has to do with what we are doing in the plant. As you know, the plant started in early last year with SueroX, but implemented the shampoo lines also in the last few months of 2021. That's another factor that allows for more flexibility, for more effective delivery of product, better logistics, better customer service and faster times in general terms to get to the market to the point of sale. You know, we have a very strong go-to-market commercial model, which allows us to, with the help now of the plant, allows us to be much more efficient in the whole chain. That's another factor that worked out very well. Finally, the consumer is reacting very, very nicely to the new Tío Nacho. Being the, I think, the only shampoo in Mexico, and it will be in Latin America, that is 100% sustainable, it's gonna be very attractive, not only for the traditional consumer of Tío Nacho, but now we are, hopefully, and we are already seeing a little bit of this, we are attracting younger consumers, which is part of the strategy behind this launch. So that would be my comment in terms of the category of shampoos. Before going to the U.S., Tonio, anything else to add? Yes, Jorge. I think that the other impact that it's worth mentioning is that, for the first time, at least in a couple of years, and this is something that Jorge and I mentioned during our remarks, cough and cold is back, which is great for our business. It's also a sign that the world is becoming more normal. Fortunately, Omicron resembles a lot the common cold. So, looking into the future, we hope that, again, the world will be more normal. What we are seeing, you know, in the first weeks of 2022 is a very strong performance in that category, and that's something that helps us also in Q4. For Genomma, that's a very important category, not only in terms of sales, but also in terms of profitability. We're very happy about that, especially because the world is becoming more normal and that category's strength is also good for us. With that, let me turn the mic back to Jorge for the U.S. One comment just on the last point you made, Tonio, is that we are very pleased as we continue developing our portfolio. We're very pleased by the fact that it's a diversified portfolio. We had an excellent 2020 in the middle of the pandemic. We had an excellent 2021, despite the fact that at the beginning of the year, there was no cough and cold season, because the other brands in our portfolio showed up in terms of market presence, et cetera. 2022 is looking very good, by the way. We have just started 2022, but as I said, and as Antonio said, given that this cough and cold season is back to normal and given the inertia of several initiatives in other categories that we have launched in the last few months and we continue launching this year, in addition to the continuous improvement that we are gonna be seeing with the supply chain, including the manufacturing plant, I say we are very bullish about what we can see in 2022. My 2022 comment includes the U.S. As I said in my comments, we think we are in a very important relevant moment in the history of our new strategy in the U.S. You may remember that in 2019, we decided to analyze and redesign the strategy in the U.S. In early 2020, we implemented a new strategy focused on key states with a new restructured team and with an improvement in the portfolio of products we were offering in the market. Now, that was looking for younger Hispanics, not only the traditional Hispanic consumer, and going to some general market consumers in a few key selected states. That during 2020 was a difficult year, as you remember, 2021 was a better year in terms of the implementation of that strategy. It is working. You don't see it in the total U.S. numbers, but if you would go and see Puerto Rico, for instance, where we have a specific focus behind the new strategy, with a focused, dedicated team, with a dedicated country manager, we're booming in Puerto Rico. We are gaining market share in all the categories in which we compete. Now we started doing the same thing in California in 2021, and we'll continue doing the same thing in other states. The number in 2021 is kind of impacted by the base, unfortunately, but that's gone now. The base, I meant, there was no cough and cold in 2021. That was a big issue versus early 2020. That was a regular cough and cold season. The antibacterial gels also that are in the base in 2020, which sales really decreased a lot as a category as a whole in 2021 because consumers are not using gels as they were using them in the middle of the pandemic. Those two truly affected the base. However, as I said, that's gone. Without having specific numbers, but the first two months of 2022 are being great months in the U.S. You will see it when we close the quarter, but the sellout as we measure it also is in the very high double digits for the first seven weeks of the year. That's a clear sign that our strategy is working and will be seen in terms of results in 2022. That's terrific. Thank you very much, Jorge and Antonio. Thank you. Thank you. As a reminder, if you'd like to be placed into question queue, please press star one at this time. One moment please while we poll for further questions. We've reached the end of our question and answer session. I'd like to turn the floor back over to Mr. Brake for any further closing comments. Okay. Thank you, operator, and thank you everyone for joining us today. As we noted, 2021 was marked by strong operating performance across all of our businesses with very good progress and continued evolution of our strategy. We're entering into 2022 well positioned to capture opportunities with very powerful momentum. Thank you very much. Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.